Raynovent Announces Approval of Category 1 Drug ZSP0678 for Clinical Trials of NASH Indication
The China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for Nonalcoholic steatohepatitis (NASH) indication.
